Commentators have offered differing opinions on the impact of yesterday’s decision by the European Patent Office (EPO) to revoke a CRISPR/Cas9 patent owned by the Broad Institute of Harvard and MIT.
In that context I was interviewed by the Life Science Intellectual Property Review
Subject
CRISPR Cas 9 - gene editing
Period
18 Jan 2018
Keywords
Gene editing, CRISPR, Broad Institute, Patents, EPO
CRISPR, EPO, European Patent Office, patent revocation, Broad Institute, Allen & Overy, ERS Genomics, Timo Minssen